Pharma IQ Members

Market Access, Trends and Outlook

View All Posts
Regina Au
Why are IO therapies buzzing today? If we look back at the history of cancer treatment, the survival rate was measured in months, which according to oncologists was a lot back then, because the mortality rate in most cancers was 100%. Most traditional chemotherapies were not well tolerated, because they would kill both cancerous and healthy cells Read more
Tags:
October 25, 2016 by Regina Au

The Clinical Trial Diary

View All Posts
Georger
Extensive investigator networks, cultivated over the course of some of the world’s largest clinical trials into the risk factors for dementia, present an exciting opportunity for the future of dementia trials. Diabetes, hypertension, stroke, vascular disease, smoking, poor diet, physical inactivity and even depression have been linked to an Read more
Tags: investigator network, clinical, clinical trials, clinical trial supply. george clinical, dementia, dementia trials, George Institute for Global Health, Dr Candice Delcourt, Professor Bruce Neal, Professor Craig Anderson
August 2, 2016 by George Clinical Representative

Artwork Matters

View All Posts
Andrew Love
In the last article I looked at the starting point of developing your organisation’s strategy, the legislation and its impact. In this article I discuss defining your solution, what to look for when picking your implementation partners and the key aspects to consider when resourcing the project team.
Tags:
May 16, 2016 by Andrew Love
Andrew Love
Continuing in this series of articles expanding on Ensuring Effective Translations, the next set of tips are to help you make sure that the information you are giving to your service provider is well prepared.
Tags: translation | Andrew Love | international pharma | market access | translator | provider | distribution
October 26, 2015 by Andrew Love

Making Tomorrow's Medicines

View All Posts
Tony Hitchcock
When we look at the current trends with what we can refer to as “next generation therapeutics”, whether it be ADCs or cell and gene therapy products, one trend is very clear, products are becoming increasingly complex in their nature. Certainly, the complexity of the manufacturing processes used to produce them clearly reflects this; hand in hand Read more
Tags: manufacturing, pharmaceuticals, pharma, biotechnologies, biotech, biopharma, therapeutics, gene therapy, cell therapies, | disposable manufacturing | vaccinces, | CMOs | pharma firms | Big Pharma | SME pharma | drug developer | Tony Hitchcock | contract development
March 22, 2016 by Tony Hitchcock
The phrase Knowledge Exchange (KE) describing collaborations between industry and the academic community is recognised as having been a key factor in the development of the bio-pharmaceutical sector over recent year
Tags: knowledge exchange, partnership, academic groups, pharma, biotech, market access, mergers and acquisitions,
December 22, 2015 by

Women in Shared Services

View All Posts
Georger
The rising presence of clinical trials (CT) in the Asia-Pacific region is predominantly driven by the East Asian region which includes China, Japan, Korea, Taiwan and Hong Kong. Over the past decade, Korea has become a global clinical trial hub and is one of the leading clinical trial destinations in the Asian region; with approximately 80% of its Read more
Tags: clinical, south korea, korea, clinical trial, clinical sites, multinational clinical study, local clinical study, Korea National Enterprise for Clinical Trials | KoNECT | CRO | contract research organisation, R&A
March 22, 2016 by George Clinical Representative

Market Access Insights

View All Posts
Dr Steven Bradshaw
On January 11th 2016, the Comité Economique des Produits de Santé (CEPS - Economic Committee for Health Products) signed on the behalf of the French Government a new agreement, the Accord cadre, with Les entreprises du médicament (LEEM - pharmaceutical companies association) on how to set reimbursed drugs prices for the next 3 years. The CEPS is Read more
Tags:
March 15, 2016 by Dr Steven Bradshaw
Dr Steven Bradshaw
With 19 therapeutic positioning reports (IPT: informe de posicionamiento terapéutico) now published, the focus and intention of the new Spanish health technology assessment paradigm can be reviewed. And in some quarters, the guidance has attracted substantial opposition. Our columnists Dr Steven Bradshaw and Dr David Carr discuss these Read more
Tags: Spain | Spanish market | Dr Steven Bradshaw | Dr David Carr | Spanish health technology assessment paradigm
December 7, 2015 by Dr Steven Bradshaw
Dr Steven Bradshaw
The austerity measures put in place as part of the &'Troika' bailout after Greece's mid-2000s financial crisis included the aim to substantially reduce national drugs spend. With the country already having one of the lowest drug prices in Europe (calculated as the average of the three lowest-price countries), additional Read more
Tags: austerity measures | pharma | Greece
December 7, 2015 by Dr Steven Bradshaw
Dr Steven Bradshaw
One year on since the launch of the UK's Early Access to Medicines Scheme (EAMS), Novartis’ investigational heart failure drug LCZ696 (sacubitril/valsartan) has become the fifth therapy to be awarded a 'promising innovative medicine' (PIM) designation. Significantly for health technology manufacturers, LCZ696 is Read more
Tags:
December 7, 2015 by Dr Steven Bradshaw

View All Posts
Dr Steven Bradshaw & Dr David Carr
Dr Steven Bradshaw and Dr David Carr of Market Access Solutions (MKTXS) discuss a new framework for conditional (pre-full license) approval of regenerative therapies in Japan … Legislation that came into force in November 2014 is paving the way for a potential influx of regenerative medicines into the Japanese market. The Pharmaceuticals, Read more
Tags:
April 13, 2015 by Dr Steven Bradshaw & Dr David Carr

Change is Good

View All Posts
Jon Wetzel
To look forward we need to first look back. From 2008-2012 we saw big pharma collide creating larger companies. Genentech-Roche, Novartis-Alcon, Pfizer-Wyeth and GlaxoSmithKline-Human Genome Sciences just to name a few. During this same time frame the economies of the world have seen crashes and upheavals causing some of these same companies to Read more
Tags: biotech | small biotech | Operational Excellence | OpEx | pharmaceutical excellence | Genentech-Roche | Novartis-Alcon | big pharma 2013 | pharma predictions 2013 | Jon Wetzel | GlaxoSmithKline-Human Genome Sciences | Pfizer-Wyeth
March 7, 2013 by Jon Wetzel

LPHII LifeSciences-Pharma-Healthcare-Innovation and Integration

View All Posts
Shirley Williams
Under the umbrella of socializing health care, I recently had the opportunity to interview Colleen Young, Founder of Healthcare Social Media Canada. The topic was: “What is the social activity in the health care space and how is it enabling our approach on health care?” I was thrilled that I could get into her schedule on two separate occasions to Read more
Tags: social media tools | social media health care | Shirley Williams | public health
December 2, 2012 by Shirley Williams
Shirley Williams
I was struck by the number of patients that do indeed blog and the reasons why they have turned to the social web. However what was more enlightening, and at the same time emotionally dampening, were the reasons why many do not tell their doctors about their blogging activities.
Tags: patient communication | patient bloggers panel | Shirley Williams
September 30, 2012 by Shirley Williams
Shirley Williams
What exciting times we are living in. Well I guess it depends on what side of the table you happen to be sitting but I think it exciting regardless. It is fair to say marketing as we know it has radically changed. The arrival of the social environment has forced traditional Marketers to rethink their strategies and tactics in the marketplace. Read more
Tags: active patients | patients | social media pharma | social media marketing | pharma marketer | pharmaceutical marketing | patient involvement | e-Patient | participatory healthcare
August 27, 2012 by Shirley Williams

Ensuring a Change for the Better

View All Posts
Cristina Falcão
Will “Fat taxes” affect consumption, and eventually obesity? The impact of imposing taxes on the consumption of certain foods depends on the responsiveness of consumers to price changes, i.e. price elasticity. It is difficult to predict how consumers will react to price changes caused by taxation.
Tags: Cristina Falcão | obesity epidemic | obesity costs | obesity | fat taxes | taxation | bariatric surgery
March 23, 2012 by Cristina Falcão
Cristina Falcão
The hardest area to improve is measurement and evaluation - pricing and reimbursement of orphan drugs are under payers’ scrutiny.
Tags: Cristina Falcão | orphan drugs | orphan drugs market | market access | pricing | rare diseases | marketing authorization | personalized medicine | reimbursement
November 15, 2011 by Cristina Falcão
Cristina Falcão
Marketing exclusivity in EU and U.S.A provided a monopolistic market for orphan drugs without “me-too”/generics competitors, to pharma companies.| Orphan drug laws and the pharma industry made great contributions towards the cure of millions of people offering from uncommon and frequently life-threatening diseases. However, it is necessary to Read more
Tags: orphan drugs | orphan drug market | personalised medicine | orphan drug laws | Cristina Falcão
October 19, 2011 by Cristina Falcão

Market Access and Value-Based Pricing

View All Posts
Stuart Carroll & Alasdair Williams
As the old aphorism goes, a New Year means a new beginning. It also provides an opportunity for all of us to make New Year resolutions – promises we make to one or more lasting personal goals, projects, or the reforming of a habit. In the world of health policy, this has added meaning. The Government continues to face opposition to its NHS Read more
Tags: value-based pricing | VBP | Stuart Carroll | Alasdair Williams | pharmaceutical pricing | Pharmaceutical Price Regulation Scheme | PPRS | NHS reforms | Andrew Lansley | George Osborne | UK Government | NHS drug availability | health economy | health economics | NHS
February 7, 2012 by Stuart Carroll & Alasdair Williams